Pentixapharm Holding Ag · XETR:PTP
Pentixapharm — FY2024 Earnings Presentation
27 slides from Pentixapharm's earnings presentation, Apr 15, 2025
Slide 1: FY 2024 Investor Call
PENTIXAPHARM FY 2024 Investor Call April 15th, 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements based on the beliefs of Pentixapharm Holding AG management. Such statements reflect current views of Pentixapharm Holding AG with respect to future events and results and are subject to risks and uncertainties. Actual results may vary
Slide 3: Agenda
Agenda 1. Company & Assets 2. Milestones in 2024 3. Financial Results 4. Clinical Update 5. Questions & Answers 3
Slide 4: Company & Assets
A UUNUEEY PENTIXAPHARM Company & Assets
Slide 5: The Company
The Company Pentixapharm Holding AG, Pentixapharm AG parent company, is listed in the Prime Standard of the Frankfurt Stock Exchange • Pentixapharm AG, a former subsidiary of Eckert & Ziegler SE, has successfully completed its spin-off into Pentixapharm Holding AG in October 2024 • Anchor investors,
Slide 6: Pentixapharm Holding AG Value Growth Strategy
Pentixapharm Holding AG Value Growth Strategy Innovate Discover, design or in-license targeted radiopharmaceutical assets with strong translational potential. Advance & De-risk pipeline Progress assets through preclinical and clinical stages to generate proof-of-concept and proof-of-efficacy data an
Slide 7: Precision in Action – Radiopharmaceuticals
Precision in Action – Radiopharmaceuticals Radioisotope: Emits gamma for the detection of PET/CT imaging visualizes tumor receptor expression disease (diagnostic) and beta or alpha radiation that penetrates beyond a single cell, enabling the destruction of cancer cells (therapeutic) Ligand: A target
Slide 8: Pentixapharm's CXCR4 targeted Theranostic Portfolio
Pentixapharm’s CXCR4 targeted Theranostic Portfolio • C-X-C chemokine receptor type 4 (CXCR4) • plays a key role in tumor growth, metastasis, and angiogenesis in various cancers • is a validated target in an array of liquid cancers (myelomas, leukemia & lymphomas) and solid tumors • can be valuable
Slide 9: Pentixapharm's Antibody Pipeline & Platform: Glyco/Protein Targets
Pentixapharm’s Antibody Pipeline & Platform: Glyco/Protein Targets The Challenge: ▪ Targeting conventional protein epitopes = high affinity, but risk of on-target/off-tumor toxicity due to normal tissue expression ▪ Targeting carbohydrate epitopes = small size and low charge of glycans lead to low a
Slide 10: Substantial Growth in the Radiopharmaceutical Market
Substantial Growth in the Radiopharmaceutical Market • Market expected to grow from $8 billion in 2023 to $12 billion in 2026 1 • ~225 clinical trials for new radioligand therapies 2 Elevated dealmaking in 2023 – 2024: 1Senior, M. Precision radiation opens a new window on cancer therapy. Nat Biotech
Slide 11: Milestones in 2024
Milestones in 2024 Corporate & Clinic 11
Slide 12: 2024 Achievements – Corporate
2024 Achievements – Corporate Acquisition of Target Autonomization from IPO in Prime Standard of the Discovery Unit of Glycotope Eckert & Ziegler SE Frankfurt Stock Exchange • Annual General Shareholder • Pipeline expansion with Meeting of Eckert & Ziegler SE • Pharmaceutical specialists EWK and rad
Slide 13: 2024 Achievements – Clinic & Regulatory
2024 Achievements – Clinic & Regulatory Clinical Milestones Regulatory Milestones • Start of Phase II investigator-initiated • Positive feedback from the FDA trial by the US National Cancer translated into a pivotal Phase III Institute (NCI) in an estimated 77 trial concept in Primary patients with
Slide 14: Financial Results
Financial Results Balance Sheet, P&L and Guidance for 2025 14
Slide 15: Balance Sheet
Balance Sheet € thousand 31-Dec-24 31-Dec-24 Assets Liabilities Non-current assets Equity Goodwill 0 Subscribed capital 24,795 Other intangible assets 35,354 Capital reserves 37,475 Property, plant and equipment 269 Net profit/loss -12,843 Deferred tax assets 0 Treasury shares -12 Financial assets 4
Slide 16: Profit & Loss
Profit & Loss € thousand Mar 18 - Dec 31, 2024 Revenue 118 Proceeds from the sale of rights/patents 6,700 Other operating income 8,480 Cost of materials and external services for research and development -3,718 Personnel expenses -1,431 Other operating expenses -8,077 Earnings before interest, taxes
Slide 17: Statement of Cash Flows
Statement of Cash Flows € thousand Mar 18 to Dec 31, 2024 Cash flow from operating activities Profit/loss -12,843 Adjustments for: Depreciation, amortization and impairments 19,044 Change in deferred taxes -3,715 Income tax payments -36 Other non-cash expenses/income -59 Increase in trade receivable
Slide 18: FY 2025 Financial Guidance
FY 2025 Financial Guidance The Company guidance for the full year 2025 is as follows: Total Loss: €23.5 million FY 2025 R&D Personnel & Other Depreciation: Grants: Expenses: OPEX: €11 million €9.5 million €3,5 million €0,7 million 18
Slide 19: Clinical Update
Clinical Update PT-001, PT-002, GT-00X 19
Slide 20: Our Development Pipeline
UU Our Development Pipeline PENTIXAPHARM : PENTIXAPHARM. PentixaTher BEL coe nowpstr ee CXCR4 Radiotheranostic A Sterne coats ww PENTIXAPHARM ww PENTIXAPHARM. wer PENTIXAPHARM. PentixaFor PT-004 CXCR4 Radiodiagnostic ww PENTIXAPHARM. ERISA Undisclosed Radiodiagnostic PENTIXAPHARM GT-00x Undisclosed
Slide 21: Pentixapharm's Lead Asset: Promising Candidate for Broad Diagnostic Use
Pentixapharm’s Lead Asset: Promising Candidate for Broad Diagnostic Use • CXCR4 is known to be overexpressed in unilateral functional adenomas causing Primary Aldosteronism • Large addressable patient population: Published estimates1 indicate that primary aldosteronism may be present in 10–20% of pa
Slide 22: [68Ga]Ga-PentixaFor PET/CT in the Subtype Diagnosis in PA
[68Ga]Ga-PentixaFor PET/CT in the Subtype Diagnosis in PA Subtyping Adrenal CT/ • Sustained Adrenal Venous Non-lateralized Sampling (AVS) Mineralocorticoid blood pressure PA receptor catheter (mostly BAH) antagonists • Increased Standard of Care (SoC) (Lifelong plasma medication) aldosterone/ renin
Slide 23: CXCR4 is Overexpressed in Hematologic Malignancies
CXCR4 is Overexpressed in Hematologic Malignancies • To this day, patients in more than 8 indications have been treated with either Y90-CXCR4 or Lu177-CXCR4*: Indication n Multiple Myeloma 41 B-cell non-Hodgkin 12 Lymphoma Diffuse Large B-cell 8 Lymphoma Follicular Lymphoma 2 Mantle cell Lymphoma 1
Slide 24: Theranostic Oncology Development Program
Theranostic Oncology Development Program Conditioning Regimen Hematologic Malignancies with bone marrow ablation and transplant back up Hematologic Systemic Therapy Malignancies Condition Regimen intended for/ with Human Stem Cell PentixaFor/ Transplant Solid Tumor PentixaTher Solid tumor with local
Slide 25: Data-driven Indication Selection for Further Clinical Development
Data-driven Indication Selection for Further Clinical Development Lymphoma Multiple Myeloma AML/ALL Solid Tumor: Bladder Ongoing: Until H1 of 2025: Until H2 of 2025: Until Q4 of 2025: First patient treated in Phase Potential Start of Phase-I/II Phase-I/II clinical progress in Investigator Initiated
Slide 26: Pentixapharm Value Inflection Points in the Near-Term
Pentixapharm Value Inflection Points in the Near-Term Primary Aldosteronism (Hypertension): PentixaFor • Acceptance by FDA of IND Application for Phase III in Primary Aldosteronism (Diagnostic) Acute Leukemia (myeloid/lymphoblastic): • Next dose cohort started in phase I/II investigator-initiated tr
Slide 27: Question & Answers
Question & Answers Phillip Eckert, Investor Relations Meet us at: Tel.: +49 30 94893232 E-Mail: phillip.eckert@pentixapharm.com • EHA Congress, Milan, June 12–15, 2025 Dirk Pleimes, Group CEO & CMO • Bio International Convention, Boston, June 16-18, 2025 Phone: +1 (646) 455-8495 E-Mail: dirk.pleimes